

CV Form

Name(中/英文)	黃偉謙 / Wei-Chien Huang, Ph.D.	
Affiliation(s)(中/英文)	中國醫藥大學 癌症生物與精準治療中心 Cancer Biology and Precision Therapeutics Center, China Medical University	
Current Position Title	Professor and Director	
E-mail/Phone Number	whuang@mail.cmu.edu.tw/04-22053366-7912	
Personal Website	https://webap.cmu.edu.tw/TchEportfolio/index_1/whuang	

個人簡歷 (No more than an A4 size paper)

Education/Training:

- 美國德州大學 MD Anderson 癌症中心分子與細胞腫瘤學系博士後研究員。
- 國立臺灣大學醫學院藥理學科博士後研究員
- 國立臺灣大學醫學院藥理學研究所博士
- 國立成功大學醫學院藥理學研究所碩士。

Professional and Research Experience:

- 中國醫藥大學 生物醫學研究所 / 藥學系 教授。
- 中國醫藥大學 癌症生物與精準治療中心 主任。
- 中國醫藥大學附設醫院 分子醫學中心 副主任 / 研究員。
- 中國醫藥大學 癌症生物學與藥物開發學位學程 主任。
- 中國醫藥大學 生物醫學研究所 副所長。
- 曾任中國醫藥大學研究發展處副研發長。
- 曾任中國醫藥大學研究發展處行政組組長。
- 優互生技股份有限公司共同創辦人。
- 研究領域:癌症訊息傳遞、抗癌藥物抗藥性、腫瘤代謝、環境致癌機制、核酸藥物及抗癌新藥開發。

Awards and Honors:

- 2026 年董大成博士基礎癌症研究獎
- 2026 年國家發展委員會「綻放計畫」創業補助。
- 2025 年第 22 屆國家新創獎「學研新創獎」。
- 2025 年國科會「科研創業計畫 (FITI)」宏碁薪傳獎。
- 2025 年 Moderna Taiwan mRNA 創新獎前十強。
- 2025 年 乳癌防治基金會優秀論文獎
- 2024 年國家生技研究園區 NBRP Pitch Day 潛力團隊獎。

Selected Publications as the major author:

1. YH He, MH Yeh, YL Wei, CH Chen, HC Chou, LC Kuan, MH Chi, SW Hu, FJ Cheng, YL Yeh, CH Yang, MY Shie, YW Chen, YJ Chen, YJ Chang, CH Yao, CH Huang, LC Liu, FJ Tsai, DY Cho, MC Hung, WC Huang*. Targeting a DDB2-dependent DNA repair vulnerability in aggressive breast cancer with lincRNA-p21-derived oligonucleotides. *Nature Communication*. Under revision.
2. FJ Cheng, YC Shen, BR Chen, SW Hu, LHH Thuong, YL Wei, YH He, YL Yeh, TW Zhang, IS Hsieh, TY Koh, YC Wu, JC Lien, Yi-Chuan Li, CH Chen, CY Tu, ML Chen, B Zhang, M Tajima, S Fagarasan, MC Hung, CH Tang*, WC Huang*. The metabolic dependency on GLUT3 mediates smoking-induced NSCLC progression. *Cancer Letters*. Under revision.
3. FJ Cheng, S Fagarasan, MC Hung, WC Huang*. Cigarette smoke reprograms tumor metabolism, immune microenvironment, and therapeutic resistance. *Biomedical Journal*. Under review. (Invited review)
4. Shen Y.C.*, Nguyen K.T.L.*, Wang B.W.*, Cheng F.J., Chen B.R., Hu S.W., Chen P.Y., Hsu J.M., Wei Y.L., Huang W.C.#, Tu C.Y.#, Chen C.H.#, PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC. *Biomedical Journal* 2026 Jun 10:101002. doi: 10.1016/j.bj.2026.101002.
5. Huang H.Y., Huang Y.-Y., Wu C.-L., Huang W.-C.#, Lai C.-L.# (2026, Jan). Smog, Sugar, and Synapses: Unraveling the PM2.5-Insulin Resistance-Alzheimer's Disease Axis. *Redox Biology*, 90:104031.
6. Hu D.-W., Huang C.-H., He Y.-H., Wei Y.-L., Hu S.-W., Cheng F.-J., Huynh T.K., Chen, B.-R., Wang B.-W., Lee D.-Y., Yeh M.-H., Chang Y.-J., Liu L.-C., Hung M.-C., and Huang W.-C.#. SLC6A14 Drives Mitochondrial Fusion and Oxidative Phosphorylation to Promote Cancer Stemness and Early-Onset of Breast Cancer. *Advanced Science* 2025. Sep 17:e10811.
7. Hu S.-W., Yeh M.-H., He Y.-H., Wei Y.-L., Cheng F.-J., Yeh Y.-L., Huynh T.K., Liu P.-T., Hu D.-W., Chang T. -H., Wang B.-W., Chen, B.-R., Lin M.-C., Lee D.-Y., Hsieh Y.-H., Hsu Y.-M., Tang C.-H., Ho P.-C., Hung M.-C., and Huang W.-C.# Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse event of anti-PD-1 antibody for Breast Cancer. *Cell Report Medicine* 2025. Oct 30:102429.
8. Hsu S.-C., He Y.-H., Chen Y.-J., Phuong U.L.N., Liu P.-T., Liu P.T., Huynh T. K., Chen Y.L., Wei Y.-L., Chou H.C., Huang W.-C.# Jeng L.-B. Disrupting DDB2-DNA Interaction by Lapatinib Enhances Chemotherapy Sensitivity. *International Journal of Biological Sciences* 2025. 21(14):6007-6024.
9. Liao WC, Chou CH, Ho MW, Chen JT, Chou SL, Huang YT, Bui NN, Wu HY, Lee CF, Huang WC#, Lai CH#. Cigarette smoke compromises macrophage innate sensing in response to pneumococcal infection. *J Microbiol Immunol Infect*. 2025, 58: 120-127.
10. Huang H.-Y., Chen C.-H., Cheng F.-J., Wang B.-W., Tu C.-Y., Chen Y.-J., He Y.-H.#, Yao C.-H.#, and Huang W.-C.# Incense-burning smoke ingredient Auramine enhances lincRNA-p21 expression for chemosensitization in p53-mutated non-small cell lung cancer. *Journal of Hazardous Materials*. 2024 Sep 15:477:135105.
11. Ho C.-Y., Wei C.-Y., Zhao R.-W., Ye Y.-L., Huang H.-C., Lee J.-C., Cheng, F.-J.#, Huang W.-C.#. Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2-positive breast cancer. *Environ Toxicol*. 2024 Jun;39(6):3389-3399.
12. Jiang Y.-J., Chao C.-C., Chang A.-C., Chen P.-C., Cheng F.-J., Liu J.-F., Liu P.-I., Huan C.-L., Guo J.-H., Huang W.-C.#, and Tang C.-H.#. Cigarette smoke-promoted increases in osteopontin expression attract mesenchymal stem cell recruitment and facilitate lung cancer metastasis. *Journal of Advanced Research*. 2022, 2022 Nov; 41: 77-87.
13. Nguyen K, Chiou J.-Y., Liu Y.-C., Cheng F.-J., Shen Y.-C., Chen C.-J., Tang C.-H., Chen C.-H., Tu C.-Y., and Huang W.-C. L-lactic acidosis confers the insensitivity to PKC inhibitors by competing for the uptake via monocarboxylate transporter. *J Cellular Physiology*. 2022, 237(1):934-948.
14. Cheng F-J, Chen C-H, Tsai W-C, Wang B-W, Yu M-C, Hsia T-C, Wei Y-L, Hsiao Y-C, Hu D-W, Ho C-Y, Li T-S, Wu C-Y, Chou W-Y, Yu Y-L, Tang C-H, Chen C-Y, Chen C-M, Hsu JL, Chen H-F, Chen Y, Tu C-Y, Hung M-C, Huang W-C. Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC. *Oncogene* 2021; 40: 1162-1175.
15. He Y.-H., Yeh M.-H., Chen H.-F., Wang T.-S., Wong R.-H., Wei Y.-L., Huynh T.-K., Hu D.-W., Cheng F.-J., Chen J.-Y., Hu S.-W, Huang C.-C., Chen Y., Yu J., Cheng W.-C., Shen P.-C., Liu L.-C., Huang C.-H., Chang Y.-J., and Huang W.-C. ERα determines the chemoresistant function of mutant p53 involving the switch between lincRNA-p21 and DDB2 expressions. *Molecular Therapy-Nucleic Acids*. 2021, 25:536-553.
16. Chen C-H, Wang B-W, Hsiao Y-C, Wu C-Y, Cheng F-J, Hsia T-C, Chen C-Y, Wang Y, Weihua Z, Chou R-H, Tang C-H, Chen Y-J, Wei Y-L, Hsu JL, Tu C-Y, Hung M-C, Huang W-C. PKC delta-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs. *Oncogene* 2021.
17. Huynh T.K, Huang C.-H., Chen J.-Y., Yao J.-H., Yang Y.-S., Wei Y.-L., Chen H.-F., Chen C.-H., Tu C.-Y., Hsu Y.-M., Liu L.-C., Huang W.-C. MiR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer. *Cancer Science*. 2021; 10: 4234-4245
18. Cheng F.-J., Huynh T.K., Huang C.-S., Hu D.-W, Wu Y.-C., Tang C.-H., Chen Y, Huang W.-C. Hesperidin is a potential inhibitor against SARS-CoV-2 infection. *Nutrients*. 2021 16;13(8):2800
19. Huynh T.K., He C.-Y., Tsai C.-H., Wang C.-K., Chen Y.-J, Bau D-T, Tu C-Y, Li T-S, Huang W-C. Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation. *International Journal of Molecular Sciences* 2019; 20. 12
20. Tu C-Y, Wang B-W, Cheng F-J, Chen C-H, Hsia T-C, Wei Y-L, Chen C-Y, Hsieh IS, Yeh Y-L, Wang L-Y, Chen C-M, Chang W-C, Huang W-C. Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression. *American Journal of Cancer Research* 2018; 8: 2575.
21. Tu C-Y, Cheng F-J, Chen C-M, Wang S-L, Hsiao Y-C, Chen C-H, Hsia T-C, He Y-H, Wang B-W, Hsieh IS, Yeh Y-L, Tang C-H, Chen Y-J, Huang W-C. Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs. *Molecular Oncology* 2018; 12: 705-723.
22. Tung J-C*, Huang W-C*, Yang J-C, Chen G-Y, Fan C-C, Chien Y-C, Lin P-S, Lung S-CC, Chang W-C. Auramine O, an incense smoke ingredient, promotes lung cancer malignancy. *Environmental Toxicology* 2017; 32: 2379-2391.
23. Chen C-H, Hsia T-C, Yeh M-H, Chen T-W, Chen Y-J, Chen J-T, Wei Y-L, Tu C-Y, Huang W-C. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701. *Molecular Oncology* 2017; 11: 1273-1287.
24. Huang W-C, Ju T-K, Hung M-C, Chen C-C. Phosphorylation of CBP by IKK alpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappa B. *Molecular Cell* 2007; 26: 75-87.